Journal article icon

Journal article

Cognitive and clinical outcomes of homocysteine-lowering B-vitamin treatment in mild cognitive impairment: a randomized controlled trial.

Abstract:

BACKGROUND: Homocysteine is a risk factor for Alzheimer's disease. In the first report on the VITACOG trial, we showed that homocysteine-lowering treatment with B vitamins slows the rate of brain atrophy in mild cognitive impairment (MCI). Here we report the effect of B vitamins on cognitive and clinical decline (secondary outcomes) in the same study. METHODS: This was a double-blind, single-centre study, which included participants with MCI, aged ≥ 70 y, randomly assigned to receive a daily...

Expand abstract
Publication status:
Published

Actions


Access Document


Publisher copy:
10.1002/gps.2758

Authors


de Jager, CA More by this author
Journal:
International journal of geriatric psychiatry
Volume:
27
Issue:
6
Pages:
592-600
Publication date:
2012-06-05
DOI:
EISSN:
1099-1166
ISSN:
0885-6230
URN:
uuid:6d3bc2c2-4f88-4926-8430-628efb7853fc
Source identifiers:
167519
Local pid:
pubs:167519

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP